MedPath
Found 58 clinical trials|View Analysis
Sort by:

Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

Phase 2
Completed
Conditions
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia in Remission
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Interventions
First Posted Date
2014-05-22
Last Posted Date
2021-08-24
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
27
Registration Number
NCT02144675
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

AML Therapy With Irradiated Allogeneic Cells

Not Applicable
Terminated
Conditions
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myelomonocytic Leukemia (M4)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Erythroleukemia (M6a)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Interventions
Drug: fludarabine phosphate
Drug: cytarabine
Biological: donor lymphocytes
Other: laboratory biomarker analysis
Drug: G-CSF
First Posted Date
2014-04-07
Last Posted Date
2021-08-24
Lead Sponsor
Rutgers, The State University of New Jersey
Target Recruit Count
6
Registration Number
NCT02105116
Locations
🇺🇸

Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, United States

Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 3
Completed
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Pure Erythroid Leukemia (M6b)
Secondary Acute Myeloid Leukemia
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Interventions
Drug: Daunorubicin
Drug: Clofarabine
Drug: Cytarabine
Drug: Decitabine
Other: Observation
Procedure: Allogeneic hematopoietic stem cell transplantation
First Posted Date
2014-03-12
Last Posted Date
2024-12-13
Lead Sponsor
ECOG-ACRIN Cancer Research Group
Target Recruit Count
727
Registration Number
NCT02085408
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States

🇺🇸

Nevada Cancer Research Foundation CCOP, Las Vegas, Nevada, United States

and more 266 locations

Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy

Phase 2
Conditions
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia in Remission
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Basophilic Leukemia
Adult Acute Eosinophilic Leukemia
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Monocytic Leukemia (M5b)
Interventions
First Posted Date
2014-02-26
Last Posted Date
2021-12-01
Lead Sponsor
Case Comprehensive Cancer Center
Target Recruit Count
31
Registration Number
NCT02071901
Locations
🇺🇸

Case Comprehensive Cancer Center, Cleveland, Ohio, United States

MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Interventions
Drug: MEK inhibitor MEK162
Drug: idarubicin
Drug: cytarabine
Other: pharmacological study
Other: laboratory biomarker analysis
First Posted Date
2014-01-30
Last Posted Date
2017-12-06
Lead Sponsor
Bruno C. Medeiros
Target Recruit Count
1
Registration Number
NCT02049801
Locations
🇺🇸

Stanford University, School of Medicine, Stanford, California, United States

Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 2
Terminated
Conditions
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Erythroleukemia (M6a)
Adult Acute Monocytic Leukemia (M5b)
Interventions
First Posted Date
2014-01-08
Last Posted Date
2019-04-05
Lead Sponsor
Steven E. Coutre
Target Recruit Count
4
Registration Number
NCT02030405
Locations
🇺🇸

Stanford University Cancer Institute, Stanford, California, United States

Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Phase 2
Terminated
Conditions
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome
Untreated Adult Acute Myeloid Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Interventions
First Posted Date
2014-01-07
Last Posted Date
2016-05-09
Lead Sponsor
Roswell Park Cancer Institute
Target Recruit Count
2
Registration Number
NCT02029417
Locations
🇺🇸

Roswell Park Cancer Institute, Buffalo, New York, United States

Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Phase 1
Terminated
Conditions
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Acute Monoblastic Leukemia (M5a)
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
Adult Acute Myeloid Leukemia With Del(5q)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Pure Erythroid Leukemia (M6b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Interventions
First Posted Date
2013-07-22
Last Posted Date
2018-10-29
Lead Sponsor
Stanford University
Target Recruit Count
17
Registration Number
NCT01904643
Locations
🇺🇸

Stanford University, School of Medicine, Stanford, California, United States

Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay

Not Applicable
Completed
Conditions
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)
Adult Erythroleukemia (M6a)
Adult Acute Megakaryoblastic Leukemia (M7)
Adult Pure Erythroid Leukemia (M6b)
Chronic Myelomonocytic Leukemia
Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable
Previously Treated Myelodysplastic Syndromes
Recurrent Adult Acute Myeloid Leukemia
Interventions
Other: antitumor drug screening assay
Drug: chemotherapy
Biological: biological therapy
First Posted Date
2013-06-07
Last Posted Date
2018-07-11
Lead Sponsor
University of Washington
Target Recruit Count
16
Registration Number
NCT01872819
Locations
🇺🇸

Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States

Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML

Phase 1
Terminated
Conditions
Adult Acute Minimally Differentiated Myeloid Leukemia (M0)
Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)
Adult Acute Myeloid Leukemia With t(8;21)(q22;q22)
Adult Erythroleukemia (M6a)
Blastic Phase Chronic Myelogenous Leukemia
Adult Acute Megakaryoblastic Leukemia (M7)
Recurrent Adult Acute Myeloid Leukemia
Adult Acute Monocytic Leukemia (M5b)
Adult Acute Myeloblastic Leukemia With Maturation (M2)
Adult Acute Myeloblastic Leukemia Without Maturation (M1)
Interventions
Drug: metformin hydrochloride
Drug: cytarabine
Other: laboratory biomarker analysis
First Posted Date
2013-05-08
Last Posted Date
2019-01-31
Lead Sponsor
Northwestern University
Target Recruit Count
2
Registration Number
NCT01849276
Locations
🇺🇸

Northwestern University, Chicago, Illinois, United States

© Copyright 2025. All Rights Reserved by MedPath